drugset / Trial / NCT04611139
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
Phase 1
Withdrawn
HonorHealth Research Institute
Merck Sharp & Dohme LLC · collabSalarius Pharmaceuticals, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF pathway.
Timeline
- Start
- 2021-12-31
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
Outcome
Outcome not reported
Stopped: “Salarius discontinued support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seclidemstat | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |